New Payment Models For Curative Treatments Have CMS’ Attention, Verma Says
Executive Summary
US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.
You may also be interested in...
New Payment Models For Cell, Gene Therapies Unlikely To Originate With Medicare – Former Official
Risk-averse decision-making climate at CMS and a likely unwillingness to commit the resources needed probably means that innovative payment arrangements for cell and gene therapies may have to start in the commercial insurance sector, Demetrios Kouzoukas suggests.
Medicare's CAR-T Payment Change Helps the Entire Regenerative Medicine Field ... A Little Bit
Alliance for Regenerative Medicine says CMS' plan to create new reimbursement category for CAR-T helps validate entire field, but it may not make it any easier for other products to navigate the payment landscape. ARM is prioritizing value-based payment legislation in its Congressional lobbying.
Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.